Hellenia speciosa for COVID-19
c19early.org
COVID-19 Treatment Clinical Evidence
COVID-19 involves the interplay of 400+ viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes 6,000+ studies for 210+ treatments—over 17 million hours of research.
Only three high-profit early treatments are approved in the US.
In reality, many treatments reduce risk,
with 25 low-cost treatments approved across 163 countries.
-
Naso/
oropharyngeal treatment Effective Treatment directly to the primary source of initial infection. -
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
-
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
-
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
-
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
-
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
-
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
-
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
-
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.
Hellenia speciosa may be beneficial for
COVID-19 according to the study below.
COVID-19 involves the interplay of 400+ viral and host proteins and factors providing many therapeutic targets.
Scientists have proposed 11,000+ potential treatments.
c19early.org analyzes
210+ treatments.
We have not reviewed Hellenia speciosa in detail.
, In-Silico Test of Myricetin, Phyllanthin, Luteolin Compounds Against SARS-CoV-2 Proteins, Pharmaceutical Sciences and Research, doi:10.7454/psr.v12i2.1284
Coronavirus disease 2019 (COVID-19), which emerged in late 2019 and was first detected in Indonesia in March 2020, has significantly reshaped the country’s public health landscape. Aside from the viral outbreak itself, a decline in immunity among the population due to excessive concern about the pandemic has also become a significant issue. This study aimed to evaluate the potential of myricetin, phyllanthin, and luteolin compounds as inhibitors of the SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) virus by targeting the main protease and spike glycoprotein receptor-binding domain proteins through in silico molecular docking. Remdesivir and favipiravir were used as comparison compounds. The molecular docking process involved several stages including structural preparation, protein preparation, method validation, and docking between the compounds with the target protein. The docking results were assessed based on binding energy values, where lower energy indicates a stronger and more stable interaction between the compound and the protein. The binding energies of myricetin, phyllanthin, luteolin, favipiravir and remdesivir compounds with the main protease protein were -6.2, -5.5, -5.3, -4,4, and -5.5 kcal/mol, respectively. The binding energies of those compounds with spike glycoprotein-RBD were -6.0, -4.2, -4.8, -6.0, and -5.3 kcal/mol, respectively. The results showed that myricetin exhibited stronger binding affinity compared to phyllanthin and luteolin and may serve as a promising inhibitor of main protease and spike glycoprotein receptor-binding domain proteins.